The pharmaceutical company Avia Pharma has acquired the Swedish pharmaceutical company Pharmaprim, with a product portfolio consisting of drugs in urology, rheumatology and endocrinology.
-Avia Pharma continues its expansion and the acquisition of Pharmaprim means that we will be able to work with products that complement Avia Pharma´s existing portfolio. Through the acquisition, we strengthen our position both in prescription as well as non-prescription drugs within women´s and men´s health. Both companies have presence in the Nordic countries, which also results in both cost and sales synergies, says Jacob Calmvik, CEO of Avia Pharma.
Avia Pharma currently promotes, among other products, Intrarosa for vaginal atrophy. Intrarosa is a local treatment, new in its kind, with DHEA as active substance. DHEA is converted to both estrogen and testosterone in the vagina.
Pharmaprim is a privately owned pharmaceutical company based in Stockholm and operating in the Nordic region. The company has a sale of approx. 15 million SEK.
-Avia Pharmas value base and strategy are well in line with Pharmaprim´s future ambitions and together we see great potential in continuing our joint growth journey, says Kjell Legernaes, former CEO of Pharmaprim, who now assumes the role of Business Director Urology at Avia Pharma.
